SIGA Technologies (NASDAQ:SIGA) announced Thursday that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) approved ...

SIGA Technologies has gained Japanese regulatory approval for TEPOXX (tecovirimat) 200mg capsules, known as TPOXX in the US, ...

On Thursday, the Japan Ministry of Health, Labour and Welfare approved SIGA Technologies (NASDAQ:SIGA) antiviral treatment ...

Infection with mpox causes a fever and swollen lymph nodes, followed by a distinctive rash that develops into pus-filled blisters. Currently, two companies of Japan and Denmark produce the vaccine ...

Regulatory decision marks first approval in Japan of an antiviral for the treatment of orthopoxviruses including smallpox, mpox and cowpoxJapan ...

More than 44% of the 10,533 confirmed mpox cases in Congo are children under 15 years old, the latest Africa CDC data shows. The vaccine from Japan will be used on children aged zero to five ...

Siga Technologies (SIGA)’ antiviral treatment Tepoxx, has received regulatory approval in Japan for the treatment of smallpox, mpox, cowpox, as ...

Mpox vaccines that young children can use will arrive from Japan next week, a crucial step in reducing the spread of the disease that has killed about 1,200 people in the Democratic Republic of ...

The antiviral drug tecovirimat does not reduce the time to lesion resolution or pain among adults with mild-to-moderate clade ...

The Democratic Republic of Congo should start to receive 3 million doses of mpox vaccine from Japan next week that can be used for children, the Africa Centers for Disease Control and Prevention ...

DAKAR, Dec 12 (Reuters) - Democratic Republic of Congo should start to receive three million doses of mpox vaccine from Japan next week that can be used on children, the Africa Centres for Disease ...